• Long-term efficacy of deucravacitinib

  • 2023/09/11
  • 再生時間： 2 分
  • ポッドキャスト

Long-term efficacy of deucravacitinib

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • During the 25th World Congress of Dermatology 2023, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Mark Lebwohl, Mount Sinai, New York, U.S. We asked about the long-term efficacy of deucravacitinib.

    Lebwohl discusses the data at 112 weeks of continuous deucravacitinib treatment. He also mentions how, by blocking tyrosine kinase 2, deucravacitinib differs from standard therapies, maintaining a high level of efficacy over time.


    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示

あらすじ・解説

During the 25th World Congress of Dermatology 2023, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Mark Lebwohl, Mount Sinai, New York, U.S. We asked about the long-term efficacy of deucravacitinib.

Lebwohl discusses the data at 112 weeks of continuous deucravacitinib treatment. He also mentions how, by blocking tyrosine kinase 2, deucravacitinib differs from standard therapies, maintaining a high level of efficacy over time.


Hosted on Acast. See acast.com/privacy for more information.
続きを読む 一部表示

Long-term efficacy of deucravacitinibに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。